A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Relapsing Forms of Multiple Sclerosis

The purpose of this study is to evaluate the safety and efficacy of elezanumab in subjects with relapsing Multiple Sclerosis (RMS).


Study Type: Interventional  (Clinical Trial)
Estimated Enrollment: 165 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Relapsing Forms of Multiple Sclerosis
Actual Study Start Date: December 11, 2018
Estimated Primary Completion Date: December 3, 2020
Estimated Study Completion Date: August 17, 2021

Arms:
- Placebo Comparator: Placebo
- Experimental: Elezanumab Dose 1
- Experimental: Elezanumab Dose 2